61 results about "Tolterodine" patented technology

Device for transdermal administration of tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, optionally together with pharmaceutically acceptable carrier(s) to a human being or an animal in order to achieve an effect against overactive bladder. Use of a compound having an effect against overactive bladder comprising tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s), for the manufacture of a composition to be administered transdermally for achieving an effect against overactive bladder. Method for achieving an effect against overactive bladder in a living body by transdermal administration of a compound comprising tolterodine, optionally encompassing salts, prodrugs and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s).

The present invention relates in general to methods of treating sweating disorders and in particular to topical compositions for the treatment of hyperhidrosis. The methods of the present invention relate to the topical application of a composition comprising a therapeutically effective amount of oxybutynin, tolterodine or a substituted benzamide such as sulpiride.

A controlled release tolterodine bead is formed having a microcrystalline cellulose core, a PVP-containing water soluble coating, a tolterodine drug layer, and a controlled release layer.

Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.

Provided is a skin irritation suppressant for transdermal preparations, having a sufficient reduction effect of skin irritation due to a drug. Also provided is a transdermal preparation comprising the skin irritation suppressant. One embodiment of the invention is a skin irritation suppressant for suppressing the skin irritation due to a drug and a pharmaceutical ingredient to be used in a transdermal preparation other than the drug, the skin irritation suppressant comprising a sterol compound selected from the group consisting of cholesterol, cholesterol derivatives and cholesterol analogs, and the drug is one or more basic drugs selected from the group consisting of tolterodine, asenapine, bisoprolol, risperidone, nicotine and citalopram, and their pharmaceutically acceptable salts.

The present invention relates to a method, preferable an oral method, for treating urinary disorders, such as unstable or overactive bladder, while minimizing the occurrences of dry mouth, dyspepsia and reduced stream of tears. The methods of the present invention comprise orally administering to a mammal, preferably a human, a pharmaceutically effective dose of an antimuscarinic agent, such as tolterodine, when needed, whereby a symptomatic relief of urgency and / or frequency is achieved.

A process for preparing Tuoteluoding and its tartrate includes condensation reaction between anti-styryl alcohol ester and methylphenol, direct alkalizing, extracting in organic solvent, vacuum distilling to remove solvent, purifying to obtain Tuoteluoding, condensation reaction on diisopropylamine, reacting on L-(+) tartaric acid to become salt, splitting it into (L-(+)-tartrate-R-Tuoteluoding) and (L-(+)-tartrate-S-Tuoteluoding), reaction of L-(+)-tartrate-S-Tuoteluoding on alkali, butyl lithium, or magnesium isopropyl bromide, and reacting no tartaric acid to obtain L-(+)-tartrate-R-Tuoteluoding.

The invention concerns novel derivatives of 3,3-diphenylpropylamines, methods for their preparation, pharmaceutical compositions containing the novel compounds, and the use of the compounds for preparing drugs. More particularly, the invention relates to novel prodrugs of antimuscarinic agents with superior pharmacokinetic properties compared to existing drugs such as oxybutynin and tolterodine, methods for their preparation, pharmaceutical compositions containing them, a method of using said compounds and compositions for the treatment of urinary incontinence, gastrointestinal hyperactivity (irritable bowel syndrome) and other smooth muscle contractile conditions.

Controlled release tolterodine beads are formed of a sugar core, an innermost sealcoat layer comprising HPMC, a tolterodine drug layer, and an outer control release layer. The thickness of the hydrophilic HPMC sealcoat layer can be used help modulate the release of the tolterodine drug.

A process for preparing tolterodine with high purity.

A pharmaceutical composition in a form of an orally deliverable liquid comprises water having in solution therein a pharmaceutically acceptable water-soluble salt of a tolterodine related compound at a therapeutically effective concentration in the composition. The composition has a pH of about 2 to about 6 and further comprises a sweetening agent and an antimicrobial agent at a concentration that is antimicrobially effective at the pH of the composition. The composition is useful for treating a muscarinic receptor mediated disorder, more particularly overactive bladder, in a subject by orally administering to the subject a therapeutically effective amount of the composition.

The invention encompasses stable multiparticulate pharmaceutical compositions of tolterodine having at least one pharmaceutically acceptable excipient and at least two populations of multiparticulates each population having tolterodine or a salt thereof and the ratio of the populations is from 90:10 to 10:90 by weight, wherein after storage for 1 month at 40° C. and 75% relative humidity the difference between the dissolution profile at 4 hours is no more than about 5% when compared to the dissolution profile at the time of manufacture.

Racemic tolterodine free base in crystalline form, tolterodine with improved purity, compositions and uses thereof, and processes of preparing the same.

A sustained release pharmaceutical composition comprising coating comprising at least one water-insoluble permeable polymer and at least one water soluble polymer and homogenous cores containing only tolterodine or a salt thereof and microcrystalline cellulose is described.

A transdermal composition comprising tolterodine having improved storage stability is disclosed. The transdermal composition comprising tolterodine contains an antioxidant to stabilize tolterodine and can be stored for a long period of time.

An oral controlled release pharmaceutical composition for muscarinic receptor antagonist, preferably tolterodine, that employs a drug core, a rapidly disintegrating or rapidly dissolving coating applied to the drug core and a controlled release coating.

The invention discloses a tolterodine gel preparation, which is mainly prepared from free alkali tolterodine, gel matrix, film-forming matrix, organosilicon elastic body, percutaneous penetration accelerators, pH regulators, humectants, and the like. During use, the gel preparation contains the film-forming matrix which can form a flexible film after being dried, and can be externally coated on the thigh, the belly, the upper arm or shoulder, and other parts; flexible and wear-resistant thin film can be rapidly formed in the selected skin region; the gel is prevented from being taken away by the clothes; and meanwhile, the application site is in an unsealed state and has good air permeability. The contained organosilicon elastic body can obviously improve the dispersibility, flexibility, wettability, glossiness, and other performances of the gel system. The prepared gel is smooth, crystal clear and fine, has no foreign body sensation on the skin after use, durable medicament and slow release, good percutaneous absorption effect, convenient use, and improves the patient compliance.

Disclosed is a composition for transdermal administration containing tolterodine. The composition comprises at least one essential oil as an abirritant to minimize skin irritation caused by tolterodine. The composition relieves skin irritation caused by tolterodine. Therefore, a successful commercial application of a tolterodine-containing transdermal preparation based on the composition can be expected.

Disclosed herein are pharmaceutical compositions comprising a therapeutically effective amount of extended release tolterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating a patient suffering from overactive bladder, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release tolterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of alleviating a side effect of treatment for overactive bladder in a patient suffering therefrom, the method comprising identifying a patient in need thereof, and administering to the patient a therapeutically effective amount of extended release tolterodine, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of pilocarpine, or a pharmaceutically acceptable salt thereof.

The invention provides a preparation method of a holothuria scabra extract. Holothurian scabra is subjected to water extraction to obtain the holothuria scabra extract. The method comprises the following steps that the internal organs of holothuria scabra are removed, and holothuria scabra is washed; holothuria scabra, processed in the last step, with the mass M1 is taken, water with the mass M2 is added to holothuria scabra, homogenate, sterilization, filtering and centrifugation are conducted, and supernatant is collected, wherein the mass ratio of M1 to M2 is 1:(8-12). Furthermore, the invention provides the holothuria scabra extract obtained by the preparation method and application of the holothuria scabra extract in preparation of medicine for treating incontinence of urine. According to the preparation method, it is discovered that the holothuria scabra extract has the function of treating incontinence of urine, the effect of the extract for treating incontinence of urine is superior to the effect of tolterodine for treating incontinence of urine, and the healing effective rate is high. Furthermore, oral liquid with the holothuria scabra extract is prepared. The oral liquidcan be applied to treatment of incontinence of urine.

The process comprises reacting a compound of formula (II), where R is a hydroxyl protecting group, and the asterisk indicates an asymmetric carbon atom, with diisopropylamine in the presence of a reducing agent; optionally converting the resulting intermediate into a salt and, if so desired, isolating it; removing the hydroxyl protecting group; and if so desired, separating the desired (R) or (S) enantiomer, or the mixture of enantiomers and / or converting the obtained compound into a pharmaceutically acceptable salt thereof. Tolterodine is a muscarinic receptor antagonist useful in treating urinary incontinence and other symptoms of urinary bladder hyperactivity.